MedTrace Logo

Safety of Estrogens in Lupus: Hormone Replacement Therapy

NCT00000419 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2013-05-03

No results posted yet for this study

Summary

Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.

Conditions

Interventions

DRUG

Premarin and Provera

Sponsors & Collaborators

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • Office of Research on Women's Health (ORWH)

    collaborator NIH

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Jill Buyon, M.D. · Hospital for Joint Diseases, Department of Rheumatology

  • Michelle Petri, M.D. · Johns Hopkins Hospital, Department of Rheumatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-04-30
Completion
2002-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000419 on ClinicalTrials.gov